Phase 2 Data of AADvac1 in Alzheimer’s Disease Published
The tau vaccine evoked a robust anti-tau antibody response, which curbed the rise in plasma NfL and CSF p-tau over two years. Cognitive decline continued.
18 RESULTS
Sort By:
Go to another page:
The tau vaccine evoked a robust anti-tau antibody response, which curbed the rise in plasma NfL and CSF p-tau over two years. Cognitive decline continued.
ACI-24 prompted an immune response without serious side effects, according to AC Immune. Researchers are gearing up for other treatment trials in DS.
Longitudinal studies in DS have pegged biomarkers and cognitive measures as potential clinical trial readouts. Hundreds of adults are anticipated to join trial-ready cohorts this year.
Go to another page: